The PROMAGEN Study: Viral pandemic link?
An exploratory, block-randomised, parallel, double-blind, single-centre, placebo-controlled superiority study with 220 overweight and obese adults with BMI 25-34.9. The probiotic group (110) took 50 billion Lab4P probiotics every day for six months and the placebo group (110) took an identical looking placebo.
Supplementation with Lab4P probiotics significantly reduced the incidence of viral specific upper respiratory tract infection symptoms particularly in older or obese adults
Gut microbiota diversity remained stable in Lab4P supplemented older adults who developed upper respiratory tract infection symptoms.
This randomised, double-blind, placebo controlled study aimed to assess the effect of 6-months supplementation with the Lab4P probiotic on body weight, plasma cholesterol and well-being in healthy overweight and obese individuals. In addition, the further analyses was carried to investigate the impact of the Lab4P probiotic on the occurrence of the specific upper respiratory tract infection (URTI) symptoms and their relationship with age, BMI and gut microbiota diversity.
Overall URTI symptoms
Season differences in the URTI symptoms occurrence
Gut microbiota and URTI symptoms associations
A randomised controlled study shows supplementation of overweight and obese adults with lactobacilli and bifidobacteria reduces bodyweight and improves well-being